ISTA touts Ph2 allergy data; Myriad nabs Rules-Based Medicine for $80M; Scientists alarmed by ESC case;

 @FierceBiotech:  Merck takes its case for boceprevir to the FDA panel. News | Follow @FierceBiotech

 @JohnCFierce: Still glowing from yesterday's FDA review of telaprevir, Vertex stock is up another $1.57 so far today, as boceprevir faces a vote. Follow @JohnCFierce

> ISTA Pharmaceuticals reports that a mid-stage study of its nasal spray for seasonal allergic rhinitis demonstrated that it was safe and effective. Story

> Salt Lake City-based Myriad Genetics announced a deal to buy Rules-Based Medicine in Austin for $80 million. Report

> Philadelphia-based Iroko Pharmaceuticals says it forged a deal to acquire iCeutica to help strengthen its work on low-dose non-steroidal anti-inflammatory drugs (NSAIDs). "We are building an industry-leading pipeline to meet a clear public-health directive defined by the US Food and Drug Administration," said John Vavricka, Iroko's CEP. "That directive is to deliver NSAIDs, one of the largest classes of pain-relieving medicines, at the lowest possible dose for the shortest possible duration." Iroko release

> Omnicare Clinical Research, a CRO, has been acquired by Nautic Partners, a private equity firm based in Providence, RI. Omnicare release

Pharma News

> Pharma grows online ad spending, despite FDA delays. News

> AZ, BMS, Bayer profits up as Sanofi's drop. Story

> Ex-GSK lawyer put loyalty ahead of law, prosecutor says. Article

> Genentech lobbies for Lucentis as eye study looms. Item

> Is J&J figuring on more foreign acquisitions? Report

> Par to pay $153M in pricing lawsuit settlement. Story

Vaccines News

> FDA clears Menactra for infants. Story 

> Merck, Sanofi start Ph3 pediatric vax trial. Item

> Immune Design recruits former Elan exec. News

> Caliber opens new TX manufacturing facility. Report 

> Gates gives $8.9M to fund new malaria vaccine approach. News 

Manufacturing News

> Label-error recalls highlight weak link. News 

> Manufacturing-savvy generic cos. set for business boost. Report

> Finally, track/trace action instead of talk. Story 

> FDA system would speed excipient screening. Article 

> Drug-promo poster collection visits Philadelphia. Report

> Teva begins ramp-up at CA injectables plant. Article 

And Finally... European scientists say they're concerned that a case before the European Court of Justice could sound the death knell for stem cell research on the continent. Story

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."